NEW YORK, Jan. 10, 2014 /PRNewswire/ -- OTC Markets
Group Inc. (OTCQX: OTCM), operator of Open, Transparent and
Connected financial marketplaces, today announced that Epigenomics
AG (OTCQX: EPGNY; Frankfurt Stock Exchange: ECX, Prime Standard), a
German-American molecular diagnostics company developing and
commercializing products for cancer screening and diagnosis, has
chosen to have its American Depositary Receipts (ADRs) trade on
OTCQX®, the best marketplace with qualified companies.
(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
)
Epigenomics begins trading today on OTCQX International, a
segment of the OTCQX marketplace reserved for high-quality non-U.S.
companies that are listed on a qualified international exchange and
provide their home country disclosure to U.S. investors. U.S.
investors can find current financial disclosures and Real-Time
Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to welcome Epigenomics to our OTCQX
marketplace," said R. Cromwell
Coulson, President and CEO of OTC Markets Group. "As
an international company with operations in Europe and the U.S., Epigenomics joins a host
of global companies that have chosen OTCQX to increase their
visibility and engagement with U.S. investors. We look
forward to working with Epigenomics' management team as they
continue to expand the company's presence in the U.S. market."
Thomas Taapken, CEO/CFO of
Epigenomics AG, commented, "We are very happy to have our ADRs now
trade on OTCQX alongside a large number of high quality
international companies. As we move forward with our U.S.
commercialization plans, this step will enable us to raise
Epigenomics' visibility among U.S. investors."
BNY Mellon will serve as Epigenomics's Principal American
Liaison ("PAL") on OTCQX, responsible for providing professional
guidance on OTCQX requirements.
Epigenomics is a molecular diagnostics company developing and
commercializing a pipeline of proprietary products for cancer.
The company's lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is
currently marketed in Europe and
is in development for the U.S. and China. Epigenomics has operations in
Europe and the U.S.
Epigenomics trades on the Frankfurt Stock Exchange under the
symbol "ECX" and in the U.S. on OTCQX under the symbol "EPGNY,"
where each ADR represents five ordinary shares.
About OTC Markets Group Inc.
OTC Markets Group Inc.
(OTCQX: OTCM) operates Open, Transparent and Connected financial
marketplaces for 10,000 U.S. and global securities. Through our OTC
Link® ATS, we directly link a diverse network of broker-dealers
that provide liquidity and execution services for a wide spectrum
of securities. We organize these securities into marketplaces to
better inform investors of opportunities and risks – OTCQX®, The
Best Marketplace with Qualified Companies; OTCQB®, The Venture
Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The
Open Marketplace with Variable Reporting Companies. Our data-driven
platform enables investors to easily trade through the broker of
their choice at the best possible price and empowers a broad range
of companies to improve the quality and availability of information
for their investors. To learn more about how we create better
informed and more efficient financial marketplaces, visit
www.otcmarkets.com.
OTC Link® ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
SOURCE OTC Markets Group Inc.